炎症小体在系统性硬化症中被激活。
Inflammasome lights up in systemic sclerosis.
机构信息
Immunology group, Faculty of Health and Life Sciences, Northumbria University, Ellison Building, Newcastle Upon Tyne, Tyne and Wear, NE2 8ST, UK.
出版信息
Arthritis Res Ther. 2017 Sep 18;19(1):205. doi: 10.1186/s13075-017-1420-z.
Abstract
Systemic sclerosis (SSc) is a pro-fibrotic condition with a poorly understood aetiology. Evidence presented by Artlett et al. in this issue suggests that the microRNA miR-155 is key, with its involvement dependent on the NLRP3 inflammasome. This links epigenetic events with inflammasome signalling in SSc and opens the door to new therapeutic strategies for the treatment of SSc.
摘要
系统性硬化症（SSc）是一种促纤维化疾病，其发病机制尚不清楚。Artlett 等人在本期发表的证据表明，microRNA miR-155 是关键，其参与依赖于 NLRP3 炎性小体。这将表观遗传事件与 SSc 中的炎性小体信号联系起来，并为 SSc 的治疗开辟了新的治疗策略。
相似文献
1
Inflammasome lights up in systemic sclerosis.炎症小体在系统性硬化症中被激活。
Arthritis Res Ther. 2017 Sep 18;19(1):205. doi: 10.1186/s13075-017-1420-z.
2
Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis.微小RNA-155在系统性硬化症成纤维细胞中过表达，并且在纤维化过程中是NLRP3炎性小体介导的胶原蛋白合成所必需的。
Arthritis Res Ther. 2017 Jun 17;19(1):144. doi: 10.1186/s13075-017-1331-z.
3
Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients.系统性硬化症患者皮肤中NLRP3炎性小体、细胞因子和血管介质的表达
Isr Med Assoc J. 2015 Jan;17(1):5-10.
4
The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.炎性小体激活的半胱天冬酶-1介导系统性硬化症中的纤维化和肌成纤维细胞分化。
Arthritis Rheum. 2011 Nov;63(11):3563-74. doi: 10.1002/art.30568.
5
Targeting TLRs and the inflammasome in systemic sclerosis.靶向系统性硬化症中的 TLRs 和炎性小体。
Pharmacol Ther. 2018 Dec;192:163-169. doi: 10.1016/j.pharmthera.2018.08.003. Epub 2018 Aug 4.
6
MicroRNA-21 Mediates Angiotensin II-Induced Liver Fibrosis by Activating NLRP3 Inflammasome/IL-1β Axis via Targeting Smad7 and Spry1.微小RNA-21通过靶向Smad7和Spry1激活NLRP3炎性小体/白细胞介素-1β轴介导血管紧张素II诱导的肝纤维化。
Antioxid Redox Signal. 2017 Jul 1;27(1):1-20. doi: 10.1089/ars.2016.6669. Epub 2016 Sep 12.
7
NLRP3 inflammasome activation from Kupffer cells is involved in liver fibrosis of Schistosoma japonicum-infected mice via NF-κB.Kupffer 细胞中的 NLRP3 炎性小体激活通过 NF-κB 参与日本血吸虫感染小鼠的肝纤维化。
Parasit Vectors. 2019 Jan 11;12(1):29. doi: 10.1186/s13071-018-3223-8.
8
MicroRNA-132 Negatively Regulates Palmitate-Induced NLRP3 Inflammasome Activation through FOXO3 Down-Regulation in THP-1 Cells.microRNA-132 通过下调 FOXO3 负向调控棕榈酸诱导的 THP-1 细胞 NLRP3 炎性小体激活。
Nutrients. 2017 Dec 18;9(12):1370. doi: 10.3390/nu9121370.
9
Regulation and Function of the Nucleotide Binding Domain Leucine-Rich Repeat-Containing Receptor, Pyrin Domain-Containing-3 Inflammasome in Lung Disease.含核苷酸结合结构域富含亮氨酸重复序列受体、含吡啉结构域的3炎性小体在肺部疾病中的调控与功能
Am J Respir Cell Mol Biol. 2016 Feb;54(2):151-60. doi: 10.1165/rcmb.2015-0231TR.
10
MicroRNA-495 Ameliorates Cardiac Microvascular Endothelial Cell Injury and Inflammatory Reaction by Suppressing the NLRP3 Inflammasome Signaling Pathway.微小RNA-495通过抑制NLRP3炎性小体信号通路减轻心脏微血管内皮细胞损伤和炎症反应。
Cell Physiol Biochem. 2018;49(2):798-815. doi: 10.1159/000493042. Epub 2018 Aug 30.
引用本文的文献
1
Targeting the NLRP3 inflammasome and associated cytokines in scleroderma associated interstitial lung disease.靶向硬皮病相关间质性肺疾病中的NLRP3炎性小体及相关细胞因子
Front Cell Dev Biol. 2023 Oct 2;11:1254904. doi: 10.3389/fcell.2023.1254904. eCollection 2023.
2
Genetical Signature-An Example of a Personalized Skin Aging Investigation with Possible Implementation in Clinical Practice.基因特征——一个个性化皮肤衰老研究的实例及其在临床实践中的可能应用。
J Pers Med. 2023 Aug 25;13(9):1305. doi: 10.3390/jpm13091305.
3
Current Concepts on the Pathogenesis of Systemic Sclerosis.系统性硬化症发病机制的现代概念。
Clin Rev Allergy Immunol. 2023 Jun;64(3):262-283. doi: 10.1007/s12016-021-08889-8. Epub 2021 Sep 6.
4
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases.风湿和肌肉骨骼疾病中的自身炎症和自身免疫。
Nat Rev Rheumatol. 2021 Oct;17(10):585-595. doi: 10.1038/s41584-021-00652-9. Epub 2021 Aug 2.
5
Interstitial lung disease in Systemic sclerosis: insights into pathogenesis and evolving therapies.系统性硬化症中的间质性肺疾病：发病机制及新兴疗法的见解
Mediterr J Rheumatol. 2018 Sep 27;29(3):140-147. doi: 10.31138/mjr.29.3.140. eCollection 2018 Sep.
本文引用的文献
1
Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis.微小RNA-155在系统性硬化症成纤维细胞中过表达，并且在纤维化过程中是NLRP3炎性小体介导的胶原蛋白合成所必需的。
Arthritis Res Ther. 2017 Jun 17;19(1):144. doi: 10.1186/s13075-017-1331-z.
2
Palmitic acid elicits hepatic stellate cell activation through inflammasomes and hedgehog signaling.棕榈酸通过炎性小体和刺猬信号通路引发肝星状细胞活化。
Life Sci. 2017 May 1;176:42-53. doi: 10.1016/j.lfs.2017.03.012. Epub 2017 Mar 18.
3
Targeting miR-155 to Treat Experimental Scleroderma.靶向miR-155治疗实验性硬皮病。
Sci Rep. 2016 Feb 1;6:20314. doi: 10.1038/srep20314.
4
MicroRNAs in fibrosis: opportunities and challenges.纤维化中的微小RNA：机遇与挑战
Arthritis Res Ther. 2016 Jan 13;18:11. doi: 10.1186/s13075-016-0929-x.
5
IL-1A rs1800587, IL-1B rs1143634 and IL-1R1 rs2234650 polymorphisms in Iranian patients with systemic sclerosis.伊朗系统性硬化症患者中白细胞介素-1A基因rs1800587、白细胞介素-1B基因rs1143634和白细胞介素-1受体1基因rs2234650的多态性
Int J Immunogenet. 2015 Dec;42(6):423-7. doi: 10.1111/iji.12212. Epub 2015 Sep 28.
6
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.一种用于治疗炎症性疾病的NLRP3炎性小体小分子抑制剂。
Nat Med. 2015 Mar;21(3):248-55. doi: 10.1038/nm.3806. Epub 2015 Feb 16.
Zotero 插件